CSO

Dr. Ranjita Shegokar holds a Ph.D. in Pharmaceutical Technology from SNDT University, India, and has completed PostDoctoral research at the Free University of Berlin, Germany, specializing in Pharmaceutics, Biopharmaceutics, and NutriCosmetics. She has extensive experience in R&D leadership roles at various multinational German pharmaceutical companies. Currently, she serves as the Chief Pharma Innovation Officer (CPO) at DiHeSys GmbH, Germany. She has authored numerous research articles and book chapters and has presented her work at various national and international conferences. She has filed multiple patent applications in the areas of drug delivery and targeting and has edited several influential books on pharmaceutical nanotechnology and drug delivery systems. Dr. Ranjita’s research excellence has been recognized with prestigious awards, including the German Innovation Award in 2022 and the German Medical Award in 2023. She has also served on the jury panel for various EU grants and awards, including the Women in Pharma Awards 2025, which honor excellence in the pharmaceutical industry. Her research interests include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs), nanoemulsions, cancer drug targeting, oral solid dosage forms (OSDFs), and the role of excipients in delivery systems. Dr. Ranjita’s professional focus encompasses R&D, intellectual property, trademark, innovation strategies, 2D/3D printed personalized medicines, preclinical models, and their translation into medical/clinical affairs.